Premium
PF 4 versus βTG as evidence for platelet activation in myeloproliferative disorders
Author(s) -
Luzzatto G.,
Fabris F.,
Mazzucato M.,
Girolami A.
Publication year - 1985
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1985.tb01709.x
Subject(s) - platelet , platelet activation , dipyridamole , medicine , thromboxane , beta thromboglobulin , myeloproliferative disorders , thromboxane a2 , endocrinology , platelet factor 4
19 patients with MPD have been studied. As described in normals, an age‐related increase in β thromboglobulin (βTG) release is observed. Such release, however, is greater in patients with myeloproliferative disorders (MPD). MPD seem therefore to cause platelet activation, allowing an earlier and more evident manifestation of physiologic ageing phenomena. PF 4 levels are near zero both in controls and patients, regardless of platelet number. This suggests that increased levels of PF 4 represent only a laboratory artifact, caused by platelet activation in vitro. Mean ability in producing thromboxane B 2 (TxB 2 ) is increased, but is perfectly normal in patients with normal platelet count and decreased in 3 thrombocythaemic patients, who seem to present an increased thrombotic risk. TxB 2 is reduced almost to zero by the administration of aspirine plus dipyridamole; contrarily, all other parameters were unaffected, either by such drugs or by AD 6, a new coumarin derivative with antiplatelet properties.